吉贝尔(688566) - 2024 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2024 reached RMB 896,534,453.46, an increase of 4.14% year-on-year[5] - Operating profit amounted to RMB 254,255,603.79, reflecting a year-on-year growth of 2.06%[5] - Net profit attributable to shareholders of the parent company was RMB 218,914,326.25, a slight decrease of 0.08% compared to the previous year[5] - Basic earnings per share decreased by 2.56% to RMB 1.14[3] - The weighted average return on net assets decreased by 1.72 percentage points to 10.50%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,515,936,604.43, up 13.86% from the beginning of the period[5] - Shareholders' equity attributable to the parent company increased by 18.03% to RMB 2,248,223,968.02[5] Sales and Revenue Growth - Sales revenue from the drug Niquilol tablets reached RMB 127,310,600, a significant increase of 41.46% year-on-year[6] Research and Development - The company is actively advancing the R&D of new drugs, including antidepressant JJH201501 in Phase III clinical trials and antitumor drug JJH201601 in Phase IIa clinical trials[6] - The company has increased R&D investment and capitalized development expenditures that meet capitalization conditions[6]